Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 21, 2013; 19(47): 8861-8866
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8861
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8861
Authors | Treated vs Untreated | Treatment | Observation time | HCC Tx | Recurrence | Survival |
Kubo et al[27] | 14 vs 10 | LVD | 1117 d | Ope | NA | Tumor-free survival |
(median) | (P = 0.0086) | |||||
Kuzuya et al[28] | 16 vs 33 | LVD | 38.0 mo vs 32.6 mo | Ope/RFA | NS | NS |
(median) | (P = 0.622) | (P = 0.623) | ||||
Li et al[29] | 43 vs 36 | LVD with/without ADV | 12 mo | Ope | NS | Overall survival |
(P = 0.077) | (P = 0.0094) | |||||
Piao et al[30] | 30 vs 40 | LVD | 24 mo | Ope/RFA | NS | NS |
(P = 0.12) | ||||||
Wu et al[31] | 518 vs 4051 | LVD/ETV/Telbivudine | 2.64 yr | Ope | P < 0.001 | P < 0.001 |
Authors | Treated vs Untreated | Treatment | Observation time | HCC Tx | Recurrence | Survival |
Someya et al[38] | 11 vs 69 | IFNα | 16 yr | Ope/RFA | P = 0.013 (High AST group) | NA |
Lai et al[39] | 35 vs 36 | IFNα | 30 mo | Inoperable | P = 0.001 (Tumor regression) | P = 0.047 |
Lo et al[40] | 40 vs 40 | IFNα | 60 mo | Ope (Stage III/IVA) | P = 0.031 | NS (P = 0.311) |
Sun et al[41] | 118 vs 118 | IFNα | 36.5 mo (median) | Ope | P = 0.048 | P = 0.0003 |
Chen et al[42] | 106 vs 109 | IFNα | 63.8 mo (median) | Ope | NS (P = 0.766) | NS (P = 0.826) |
- Citation: Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 8861-8866
- URL: https://www.wjgnet.com/1007-9327/full/v19/i47/8861.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i47.8861